Nikiforow, S., Mahadeo, K., Chaganti, S., Beitinjaneh, A., Choquet, S., Dierickx, D., … Baiocchi, R. (2025). Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease. In Blood (Vol. 146, pp. 1934–1934). American Society of Hematology. https://doi.org/10.1182/blood-2025-1934

Nikiforow, Sarah, Kris Mahadeo, Sridhar Chaganti, Amer Beitinjaneh, Sylvain Choquet, Daan Dierickx, Armin Ghobadi, et al. “Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease.” In Blood, 146:1934–1934. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-1934.

Nikiforow S, Mahadeo K, Chaganti S, Beitinjaneh A, Choquet S, Dierickx D, et al. Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease. In: Blood. American Society of Hematology; 2025. p. 1934–1934.

Nikiforow, Sarah, et al. “Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 1934–1934. Crossref, doi:10.1182/blood-2025-1934.

Nikiforow S, Mahadeo K, Chaganti S, Beitinjaneh A, Choquet S, Dierickx D, Ghobadi A, Valenti R, Friedetzky A, Roye S, Reshef R, Prockop S, Baiocchi R. Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease. Blood. American Society of Hematology; 2025. p. 1934–1934.